Company Filing History:
Years Active: 1999-2019
Title: Anne Barbara Cropp: Innovator in Therapeutic Antibodies
Introduction
Anne Barbara Cropp is a distinguished inventor based in Madison, CT (US). She has made significant contributions to the field of therapeutic dosing regimens, particularly in the treatment of disorders characterized by elevated low-density lipoprotein cholesterol (LDL-C) levels. With a total of 3 patents, her work has garnered attention in the pharmaceutical industry.
Latest Patents
One of her latest patents focuses on "Treatment with anti-PCSK9 antibodies." This invention relates to therapeutic dosing regimens that utilize a dose reduction strategy for treating patients with marked elevations of LDL-C in their plasma. The regimen involves administering an anti-proprotein convertase subtilisin kexin type 9 (PCSK9) antagonist antibody, starting with an initial dose of at least about 100 mg. Subsequent doses may be the same as or at least half of the initial dose, depending on the patient's LDL-C levels.
Another notable patent is for a "Composition containing amlodipine or a pharmaceutically acceptable salt thereof, and an ACE inhibitor." This invention outlines methods for treating congestive heart failure in mammals, particularly humans, through the co-administration of amlodipine, an ACE inhibitor, and optionally a diuretic and/or digoxin.
Career Highlights
Anne Barbara Cropp is currently associated with Pfizer Corporation, where she continues to innovate in the field of pharmaceuticals. Her work has been instrumental in developing new therapeutic strategies that improve patient outcomes.
Collaborations
She collaborates with Allen R. Kraska, contributing to the advancement of medical treatments through their combined expertise.
Conclusion
Anne Barbara Cropp's contributions to the field of therapeutic antibodies and her innovative patents highlight her role as a leading inventor in the pharmaceutical industry. Her work continues to pave the way for advancements in treatment methodologies.